A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection

A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection Publisher

Afshar ZM¹ ; Babazadeh A² ; Janbakhsh A¹ ; Bayani M² ; Ramezani E³ ; Khaneshan AS⁴ ; Ebrahimpour S²

Source: Cor et Vasa Published:2021

Abstract

Coronavirus disease 2019 (COVID-19) pandemic has spread rapidly across the world and is introduced as a global health crisis. COVID-19 is one of the threatening pandemics in history involving many organs, including the cardiovascular system. The cardiovascular involvements, such as myocardial injury, myocarditis, acute myocardial infarction, dysrhythmias, and heart failure, have been reported in the COVID-19 patients. Currently, there is no specific antiviral treatment for COVID-19; though, some therapies such as interferon, remdesivir, ribavirin, favipiravir, and tocilizumab are being used. The medications used to treat COVID-19 may have cardiovascular adverse events or interact with some cardiovascular drugs. The most concerning conditions caused by these medications are QTc prolongation and torsades de pointes (TdP), which might cause abrupt death. Here, we describe cardiac adverse effects and potential interactions of COVID-19 medications with cardiovascular agents. © 2021, CKS.

Related Docs

View other Related Docs

1. Cardiovascular Complications of Covid-19: Pharmacotherapy Perspective, Cardiovascular Drugs and Therapy (2021)

2. The Situation of Small Molecules Targeting Key Proteins in Combatting Sars-Cov-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications, Mini-Reviews in Medicinal Chemistry (2022)

3. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)

Experts (# of related papers)

View all Related Experts

Azita Hajhossein Talasaz (4)

Hossein Khalili (2)

Style	Citing Format
MLA	Afshar ZM, et al.. "A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection." Cor et Vasa, vol. 63, no. 3, 2021, pp. 359-363.
APA	Afshar ZM, Babazadeh A, Janbakhsh A, Bayani M, Ramezani E, Khaneshan AS, Ebrahimpour S (2021). A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection. Cor et Vasa, 63(3), 359-363.
Chicago	Afshar ZM, Babazadeh A, Janbakhsh A, Bayani M, Ramezani E, Khaneshan AS, Ebrahimpour S. "A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection." Cor et Vasa 63, no. 3 (2021): 359-363.
Harvard	Afshar ZM et al. (2021) 'A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection', Cor et Vasa, 63(3), pp. 359-363.
Vancouver	Afshar ZM, Babazadeh A, Janbakhsh A, Bayani M, Ramezani E, Khaneshan AS, et al.. A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection. Cor et Vasa. 2021;63(3):359-363.
BibTex	@article{ author = {Afshar ZM and Babazadeh A and Janbakhsh A and Bayani M and Ramezani E and Khaneshan AS and Ebrahimpour S}, title = {A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection}, journal = {Cor et Vasa}, volume = {63}, number = {3}, pages = {359-363}, year = {2021} }
RIS	TY - JOUR AU - Afshar ZM AU - Babazadeh A AU - Janbakhsh A AU - Bayani M AU - Ramezani E AU - Khaneshan AS AU - Ebrahimpour S TI - A Review of Cardiovascular Involvements Associated With Medications Used to Treat Covid-19 Infection JO - Cor et Vasa VL - 63 IS - 3 SP - 359 EP - 363 PY - 2021 ER -

Science Communicator Platform

Authors

Abstract